Information provided by Titan Support is for informational and general educational purposes only and is not investment or financial advice. Unlike the majority of the other robos, Titan is an asset manager that should be judged differently. Many brokerage firms have already submitted their reports for TTNP stocks, with Maxim Group repeating the rating for TTNP by listing it as a “Buy.” The predicted price for TTNP in the upcoming period, according to Maxim Group is $4 based on the research report published on June 26th of the previous year 2019. You have entered an incorrect email address! Titan does an excellent job providing information and updates on market conditions and the investment strategy. The investment program does not mirror this index and the volatility may be materially different than the volatility of the S&P 500. Click here to access the Options Profits Trading Guide now. Hedge funds often cost around 2% in management fees and an additional 20% in performance fees. Certain investments are not suitable for all investors. All-Time, 2018, and 2019 YTD figures represent performance of a hypothetical account created on 2/20/18, 2/20/18, and 1/1/19, respectively, using Titanâs investment process for an aggressive portfolio, not an actual amount. The stock’s price range for the 52-week period managed to maintain the performance between $0.09 and $0.55. This is nearly ~2x the market's return, and more than ~3x that of other advisors such as Betterment and Wealthfront. Salesforce.com (CRM) +40% Based on Titan Pharmaceuticals Inc. (TTNP), the company’s capital structure generated 309.91 points at debt to equity in total, while total debt to capital is 75.60. For every $1 invested, it generates more over time. Data for the 3-month Treasury Bill rate is sourced from the Federal Reserve Bank of St. Louisâs website. Titan also scores points in this category for avoiding any use of proprietary funds in their investment manager. Past performance is no guarantee of … Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -30.40%. Total debt to assets is 46.64, with long-term debt to equity ratio resting at 290.93. Titan would score closer to the full points if they offered an easy way to compare one’s account to a standard benchmark. In addition, Titan Pharmaceuticals Inc. saw -30.40% in overturn over a single year, with a tendency to cut further losses. TTNP stocks went up by 28.06% for the week, with a monthly drop of -12.04% and a quarterly performance of -54.66%, while its annual performance rate touched -19.68%. High integrity, reliable guardians of capital. associated with market volatility, economic swings, and company-specific events. Titan Invest is an SEC registered investment adviser. Based on monthly moving average Titan Pharmaceuticals is performing at about 0% of its full potential. Titan’s investment advisory services are available only to residents of the United States in jurisdictions where Titan is registered. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.31. Press Release reported on 11/02/20 that Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma’s Kappa Opioid Agonist Peptide, JT-09, Plus, the 36-month beta value for TTNP is at 0.74. Please see Disclosures below regarding returns. Titan Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. Still, as we compare Titan to a robo, it is on the pricier end. The true measure of profitability. We also interviewed @chriskcos at @BlooomInc! The 1-year high price for the company’s stock is recorded $0.5450 on 03/03/20, with the lowest value … Titan’s investment advisory services are available only to residents of the United States in jurisdictions where Titan is registered. © Copyright 2020 Whisker Technologies, Inc. All rights reserved. New York Times (NYT) -2% Why Nordic American Tankers Limited (NAT)’s Most Recent Report Reveals Some Hints About Its Future, Buy or Sell Triumph Group Inc. (TGI) Stock Now | Don’t Try to Be a Top Gun, JinkoSolar (JKS) Stock To Rise Benefiting From Global Solar Efforts, U.S. Markets: All Eyes On The Fate Of Economic Stimulus Package, Tesla Inc. (TSLA) Speeding Its EV Efforts Up In China To Maintain Lead, Reed’s Inc. (NASDAQ: REED) has upgraded forecasts following a decent quarterly report. By using this website, you accept our Terms of Use and Privacy Policy. TTNP stocks went up by 28.06% for the week, with a monthly drop of -12.04% and a quarterly performance of -54.66%, while its annual performance rate touched -19.68%. Smartsheet (SMAR) +20% Titan’s goal is to make the benefits of a hedge fund accessible to the general public by using modern robo-advisor technology. Apple (AAPL) +22% Titan Invest is an SEC registered investment adviser. You can read further details here. All-Time IRR, alpha, beta, and Sharpe ratios are from Titanâs launch date of 2/20/18 through 3/29/19. Any historical returns, expected returns, or probability projections, are hypothetical in nature and may not reflect actual future performance. Sharpe ratio is a risk-adjusted measure, calculated using standard deviation and excess return to determine reward per unit of risk. Past performance is no guarantee of future results. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A (“Molteni”) and Horizon Credit LLC II (“Horizon”), as well as its agreement to acquire JT Pharmaceuticals, Inc.’s (“JT Pharma”) kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus. Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities. Through the agreement, DraftKings BnB technology will continue to drive MansionBet’s... Intel reports third quarter earnings showing an unexpected dip in its data center segment leading the stock price to plunge 12% on Friday. Before investing, consider your investment objectives and Titanâs fees. Titan also scores points in this category for avoiding any use of proprietary funds in their investment … TTNP stocks went up by 28.06% for the week, with a monthly drop of -12.04% and a quarterly performance of -54.66%, while its annual performance rate touched -19.68%. All-Time IRR (internal rate of return) is net of fees and includes dividends and other adjustments. Before investing, consider your investment objectives and Titan’s fees. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. The majority of Flagship co's continue to be massive beneficiaries of secular tailwinds accelerated by COVID-19. Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. Read more about that here. Titan offers a zero-minimum initial investment, making it accessible to all investors. See full disclosures. support@titanvest.com. Additionally, Titan lacks customer experience features that include the ability to chat and account aggregation software to manage one’s holistic picture. The average price from analysts is $0.80. Even though it is essential to pay attention to. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolioâs performance during the time period will be provided upon request. During the last 5 trading sessions, TTNP rose by +27.33%, which changed the moving average for the period of 200-days by -53.37% in comparison to the 20-day moving average, which settled at $0.1273. Since inception in early 2018, Titan has delivered net annualized returns in excess of the S&P 500, with positive alpha and higher reward per unit of risk (Sharpe ratio). We value your privacy and will never sell your personal information. Also, the investment strategy is clearly outlined and accessible to all new investors. Intel Corporation... One thing that got our attention from over the weekend was Nvidia’s deal to purchase chip designer Arm from SoftBank Group. A beta higher than 1.0 indicates the investment has been more volatile than the benchmark and a beta of less than 1.0 indicates that the investment has been less volatile than the benchmark. Refer to Titan Investâs Program Brochure for more information. info@backendb.com. Account holdings are for illustrative purposes only and are not investment recommendations. 1973 Washington Valley Road Raw Stochastic average of Titan Pharmaceuticals Inc. in the period of last 50 days is set at 22.97%. We believe these are the good guys: long-term oriented and rigorous in their research. The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 22801419 for the day, which was evidently higher, when compared to the average daily volumes of the shares. Titan would score closer to the full points if they offered an easy way to compare one’s account to a standard benchmark. Titan Opportunities had a strong start as well, up +8% in August vs. the Russell 2000 index down -1%. Titan Invest Performance Titan Invest strives for transparency which is why they have beefed up their performance and reporting data: Titan provides comparisons of their returns against popular investment benchmarks. Those same returns also … Past performance is no guarantee of future … The receivables turnover for the company is 2.55 and the total asset turnover is 0.31. Over the last 50 days, in opposition, the stock is trading -38.88% lower at present. The shares increased approximately by 28.06% in the 7-day charts and went up by -12.04% in the period of the last 30 days. With that said, we have maintained our system of review for consistency. A positive alpha of 1.0% means the portfolio has outperformed its benchmark index by 1.0%. Stay heavily invested in Titan Flagship and Opportunities, and start to deploy spare cash on dips. Performance results were prepared by Titan Invest, and have not been compiled, reviewed or audited by an independent accountant. The simple moving average for the period of the last 20 days is -2.30% for TTNP stocks with a simple moving average of -49.30% for the last 200 days. Titan Pharmaceuticals Inc. (TTNP) full year performance was -19.68% Twilio (TWLO) -3%, Anaplan (PLAN) +31% We conservatively assume this trend will normalize eventually. All-Time IRR, alpha, beta, and Sharpe ratios are from Titanâs launch date of 2/20/18 through 3/29/19. Hard to replicate.